Clarus Lifesciences II, L.P.

Clarus Lifesciences II, L.P. discloses dealings in 7 companies, chiefly Achillion Pharmaceuticals Inc, Tetralogic Pharmaceuticals Corp and Aerie Pharmaceuticals Inc. In total, 67 filings cover trades dated from 5 September 2008 to 22 March 2019.

Both buying and selling appear: 8 purchases worth €31.2M, against 38 sales worth €65.1M. Sales outweigh purchases by €33.9M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 4 share grants. Since January 2019: no purchases and 1 sale on the market.

In size, the median ticket on the buying side is €3.2M.

The newest entry dates from 22 March 2019: an open-market sale of €38.0M, in NanoString Technologies Inc. The clock since the last published purchase (30 June 2015) now reads 4,134 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.